These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37984551)

  • 1. Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study.
    Laber DA; Patel PC; Logothetis CN; Patel AK; Jaglal M; Haider M; Visweshwar N; Rajasekaran-Rathnakumar G; Eatrides J
    Eur J Haematol; 2024 Mar; 112(3):450-457. PubMed ID: 37984551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.
    Che M; Moran SM; Smith RJ; Ren KYM; Smith GN; Shamseddin MK; Avila-Casado C; Garland JS
    Kidney Int; 2024 May; 105(5):960-970. PubMed ID: 38408703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
    Gäckler A; Schönermarck U; Dobronravov V; La Manna G; Denker A; Liu P; Vinogradova M; Yoon SS; Praga M
    BMC Nephrol; 2021 Jan; 22(1):5. PubMed ID: 33407224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
    Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
    BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
    Rondeau E; Scully M; Ariceta G; Barbour T; Cataland S; Heyne N; Miyakawa Y; Ortiz S; Swenson E; Vallee M; Yoon SS; Kavanagh D; Haller H;
    Kidney Int; 2020 Jun; 97(6):1287-1296. PubMed ID: 32299680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
    Ariceta G; Dixon BP; Kim SH; Kapur G; Mauch T; Ortiz S; Vallee M; Denker AE; Kang HG; Greenbaum LA;
    Kidney Int; 2021 Jul; 100(1):225-237. PubMed ID: 33307104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
    Phillips EH; Westwood JP; Brocklebank V; Wong EK; Tellez JO; Marchbank KJ; McGuckin S; Gale DP; Connolly J; Goodship TH; Kavanagh D; Scully MA
    J Thromb Haemost; 2016 Jan; 14(1):175-85. PubMed ID: 26559391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.
    Cammett TJ; Garlo K; Millman EE; Rice K; Toste CM; Faas SJ
    Mol Diagn Ther; 2023 Jan; 27(1):61-74. PubMed ID: 36329366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.
    Ito N; Hataya H; Saida K; Amano Y; Hidaka Y; Motoyoshi Y; Ohta T; Yoshida Y; Terano C; Iwasa T; Kubota W; Takada H; Hara T; Fujimura Y; Ito S
    Clin Exp Nephrol; 2016 Apr; 20(2):265-72. PubMed ID: 26156042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
    BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan.
    Ito S; Hataya H; Ashida A; Hamada R; Ishikawa T; Ishikawa Y; Shimono A; Konomoto T; Miyazawa T; Ogura M; Tanaka K; Kagami S
    Nephrol Dial Transplant; 2023 Feb; 38(2):414-424. PubMed ID: 35438790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V; Gupta M; Elrifai M; Moftakhar B; Ensley MJ; Vachharajani TJ; Sethi SK; Raina R
    Ther Apher Dial; 2018 Apr; 22(2):178-188. PubMed ID: 29250893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series.
    Martins M; Bridoux F; Goujon JM; Meuleman MS; Ribes D; Rondeau E; Guerry MJ; Delmas Y; Levy B; Ducloux D; Kandel-Aznar C; Le Fur A; Garrouste C; Provot F; Gibier JB; Thervet E; Bruneval P; Rabant M; Karras A; Dragon Durey MA; Fremeaux-Bacchi V; Chauvet S
    Am J Kidney Dis; 2022 Sep; 80(3):341-352. PubMed ID: 35217094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
    Kourouklaris A; Ioannou K; Athanasiou I; Panagidou A; Demetriou K; Zavros M
    J Med Case Rep; 2014 Sep; 8():307. PubMed ID: 25219386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
    Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
    J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.
    Dixon BP; Kavanagh D; Aris ADM; Adams B; Kang HG; Wang E; Garlo K; Ogawa M; Amancha P; Chakravarty S; Heyne N; Kim SH; Cataland S; Yoon SS; Miyakawa Y; Luque Y; Muff-Luett M; Tanaka K; Greenbaum LA
    Kidney Med; 2024 Aug; 6(8):100855. PubMed ID: 39105067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD; Bannerman F; Beresford MW; Oni L
    BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.